MOGAD – Medxy AI

French Registry Data Show Marked Declines in Relapse Activity and Faster Diagnosis in AQP4+NMOSD and MOGAD From 2010 to 2024

By MedXY 05/26/2026

A nationwide French cohort found earlier diagnosis, falling relapse rates, and major treatment shifts in AQP4+NMOSD and MOGAD, with rituximab linked to lower disability risk in AQP4+NMOSD and overall milder disability trajectories in MOGAD.

Neurology news

Treatment Discontinuation in Patients With Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease

By MedXY 05/13/2026

In adults with MOGAD, stopping maintenance therapy was associated with a low 1-year relapse risk, especially after longer treatment and a longer relapse-free interval. The findings support individualized decisions and close follow-up after discontinuation.

Neurology news Ophthalmology

Why the New MS Diagnostic Criteria Require Caution: High Frequency of MOGAD and NMOSD in Optic Neuritis Patients

By MedXY 03/30/2026

A retrospective study reveals that 24% of patients meeting the latest MS criteria following optic neuritis actually have MOGAD or NMOSD, emphasizing the need for antibody testing to prevent misdiagnosis.

Neurology news Ophthalmology

Navigating the Diagnostic Overlap: Why 24 Percent of Patients Meeting Minimal MS Criteria for Optic Neuritis Require Antibody Testing

By MedXY 03/18/2026

A multicenter study reveals that nearly one-quarter of patients meeting the newest multiple sclerosis criteria for optic neuritis actually have MOGAD or NMOSD, emphasizing the critical role of antibody screening and detailed orbital MRI in clinical practice.